GLP-1 medications may slow aging processes
Recent research suggests that GLP-1 medications, used for weight loss and diabetes management, may also slow the body’s aging processes, potentially contributing to a longer lifespan, reports BritPanorama.
These medications have demonstrated benefits beyond weight management, including improvements in cardiovascular and metabolic health. Studies indicate that they lower risks of heart, kidney, and liver disease, while also aiding in reducing sleep apnea and inflammation—factors that commonly accompany aging.
Dr. Danica Chen from the University of California at Berkeley notes, “Aging is the biggest risk factor for many diseases, and if we can target aging itself, we might be able to treat all kinds of diseases associated with aging.”
Current investigations are focused on the biological markers of aging to understand how GLP-1 medications may affect aging at a cellular level.
Though the research is still in its early stages, scientists caution that the extent of these benefits is not yet clear. Notably, it remains to be seen whether the positive effects of these medications are limited to individuals who are overweight or have diabetes, or whether they could also slow aging in otherwise healthy individuals.
Experts assert that it is premature for individuals to use GLP-1 medications solely with the hope of extending lifespan. Dr. James Kirkland of Cedars-Sinai Medical Center raised concerns about non-diabetic individuals experimenting with these drugs: “The question is what happens in lean younger non-diabetic individuals, especially over the long term.” He warned against overinterpreting current findings.
Measuring biological clocks
Recent studies have generated excitement about potential anti-aging effects. Dr. Kevin Duffin from Eli Lilly observed a reduction in biological age by three to six years among those using tirzepatide, one of the medications in the GLP-1 family. However, he emphasized that this change, while significant, does not imply radical changes in aging.
The study involved over 700 adults who were overweight but did not have diabetes. Results were based on epigenetic clocks, which track the biological age of tissues based on gene expression. Notably, biological aging among participants using tirzepatide advanced more slowly, suggesting a potential for the medication to positively impact aging processes.
Limitations in the study exist; it lacked a control group not using weight-loss medications, and the follow-up period was relatively short. Nevertheless, there is optimism for more extensive studies in the future that could yield further insights into the long-term effects of GLP-1 medications.
As Dr. Duffin stated, “It’ll be very interesting to see what happens at four or five years after treatment with a GLP-1.”
Moreover, questions remain about whether the aging benefits are specifically due to the medications or simply a result of weight loss. Studies comparing calorie-restricted diets and GLP-1 treatments in mice are underway to clarify this aspect.
Broader implications of GLP-1 medications
Similar to tirzepatide, semaglutide—marketed as Wegovy and Ozempic—has shown promising anti-aging benefits. Research indicates it can reduce the heart’s biological age and has shown potential improvements in the biological age of various organs such as the lungs, kidneys, and pancreas.
Dr. Alejandro Aguayo-Orozco of Novo Nordisk points out that benefits of GLP-1 medications extend beyond mere weight loss and blood sugar control, suggesting a systemic impact on health. The ongoing exploration of these medications’ roles in aging continues to highlight their potential to address multiple health issues simultaneously.
As researchers pursue further investigation into these promising outcomes, the significance of GLP-1 medications in aging management unfolds, suggesting a new frontier in their application that warrants close attention.
